Compartmentalized Liquid Pharmaceutical Ingredients for API Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Liquid pharmaceutical formulations face issues such as rapid reactivity of ingredients leading to reduced potency and stability, making it challenging to maintain active agents in a stable liquid form for extended periods.
Innovation Solution
A compartmentalized system separates active pharmaceutical ingredients (APIs) and excipients into discrete liquid forms, isolating them until needed for admixing to form a finished product, thereby reducing degradation and extending potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If ingredients are combined in a liquid pharmaceutical formulation, then the formulation can be administered conveniently, but the ingredients react rapidly leading to reduced potency and stability
Solution Approach 1:
The patent divides the liquid pharmaceutical formulation into separate compartments, each containing specific ingredients (e.g., active agent in one compartment, reactive excipients in another). This segmentation prevents unwanted chemical reactions between incompatible ingredients while maintaining the liquid formulation's convenience for administration. The compartments can be mixed only when needed for administration.
2Stability of the object's composition
If ingredients are kept in separate compartments, then stability and potency are maintained, but the system complexity increases
Solution Approach 1:
The patent employs nested compartments where smaller compartments containing specific ingredients are placed within larger containment structures. This nesting approach maintains stability by isolating reactive ingredients while minimizing the overall system complexity through efficient space utilization and integrated design. The nested structure allows multiple ingredients to be stored separately yet within a unified system.
3Duration of action of stationary object
If liquid formulation is used for extended storage, then convenience is maintained, but degradation of active agent occurs
Solution Approach 1:
The patent performs preliminary separation of ingredients into different compartments before storage, preventing degradation reactions from occurring in the first place. The active agent is pre-isolated from reactive excipients in separate compartments, allowing extended storage while maintaining potency. The compartments are designed to remain stable over extended periods until administration is needed.
Data Source
AI summary
A system of compartmentalized ingredients for a liquid pharmaceutical formulation having a first vessel including a cellular energy inhibitor according to formula I in a first liquid carrier, wherein R is selected from one of OR′, N(R″)2, C(O)R″, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, C6-C12 heteroaryl, H, or an alkali metal, where R′ is selected from one Br R of H, an alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R′″, where R1 is selected from one of SH, C1-C6 alkyl, or C6-C12 aryl, and where R′″ is selected from one of H, C1-C20 alkyl or C6-C12 aryl, and a second vessel including an excipient in a second liquid carrier that is chemically reactive with the cellular energy inhibitor, wherein admixing the first liquid carrier with the CA second liquid carrier creates a finished liquid dosage form.